PHASE I TRIAL OF SUNITINIB PLUS IMATINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

被引：0
|
作者：
Lopez Pousa, A. [1 ]
Paz-Ares, L. [2 ]
Pericay, C. [3 ]
Garcia Del Muro, X. [4 ]
Flor, M. J. [5 ]
机构：
[1] Hosp Sta Creu & St Pau, Barcelona, Spain
[2] Hosp Virgen del Roc, Seville, Spain
[3] Corp Sanitaria Parc Tauli Inst Univ, Sabadell, Spain
[4] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[5] Hosp Virgen del Rocio, Oncol Serv, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [21] Efficacy of Sunitinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
    Cubukcu, Sinem
    Kanat, Ozkan
    Cubukcu, Erdem
    Olmez, Omer Fatih
    Canhoroz, Mustafa
    Avci, Nilufer
    Hartavi, Mustafa
    Deligonul, Adem
    Seyhan, Serdar
    Ayyildiz, Aylin
    Tasdemir, Unal
    Manavoglu, Osman
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2014, 5 (04)
  • [22] Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    Bauer, S.
    Hilger, R. A.
    Muehlenberg, T.
    Grabellus, F.
    Nagarajah, J.
    Hoiczyk, M.
    Reichardt, A.
    Ahrens, M.
    Reichardt, P.
    Grunewald, S.
    Scheulen, M. E.
    Pustowka, A.
    Bock, E.
    Schuler, M.
    Pink, D.
    BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1155 - 1162
  • [23] Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    S Bauer
    R A Hilger
    T Mühlenberg
    F Grabellus
    J Nagarajah
    M Hoiczyk
    A Reichardt
    M Ahrens
    P Reichardt
    S Grunewald
    M E Scheulen
    A Pustowka
    E Bock
    M Schuler
    D Pink
    British Journal of Cancer, 2014, 110 : 1155 - 1162
  • [24] Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT plus gastrointestinal stromal tumors (GIST).
    von Mehren, M.
    Heinrich, M. C.
    Joensuu, H.
    Blanke, C. D.
    Wehrle, E.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
    Paz-Ares, Luis
    Garcia del Muro, Xavier
    Grande, Enrique
    Gonzalez, Paloma
    Brosa, Max
    Diaz, Silvia
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (12): : 831 - 839
  • [26] Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
    Luis Paz-Ares
    Xavier García del Muro
    Enrique Grande
    Paloma González
    Max Brosa
    Silvia Díaz
    Clinical and Translational Oncology, 2008, 10 : 831 - 839
  • [27] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [28] Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
    Italiano, Antoine
    Cioffi, Angela
    Coco, Paola
    Maki, Robert G.
    Schoffski, Patrick
    Rutkowski, Piotr
    Le Cesne, Axel
    Duffaud, Florence
    Adenis, Antoine
    Isambert, Nicolas
    Bompas, Emmanuelle
    Blay, Jean-Yves
    Casali, Paolo
    Keohan, Mary Louise
    Toulmonde, Maud
    Antonescu, Cristina R.
    Debiec-Rychter, Maria
    Coindre, Jean-Michel
    Bui, Binh
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) : 1551 - 1559
  • [29] EFFICACY AND TOLERABILITY OF NILOTINIB IN PATIENT WITH IMATINIB AND SUNITINIB RESISTANT GASTROINTESTINAL STROMAL TUMORS (GIST): A CASE REPORT
    Pace, R.
    Amarisse, M.
    Cigliano, L.
    Rauco, A. M.
    De Santis, G.
    Capparella, V
    Liberati, F.
    Lugini, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [30] Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors
    Daughety, Molly M.
    Heinrich, Michael C.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (06): : 659 - 670
12345